Where is Hugel located?

Hugel is headquartered in Chuncheon-si, South Korea.

How many employees does Hugel have?

As of May 31, 2026, the latest employee count at Hugel is 6.

Is Hugel a funded company?

Hugel is a funded company, having raised a total of $***** in its 1st and only funding round.

How much is Hugel worth?

The last known valuation of Hugel was $***** as of Jun 06, 2017.

Where does Hugel rank among its competitors?

Hugel ranks 7th amongst 173 active competitors, of which 42 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Shaperon, which secured $5.82M in Apr, 2026.

Who are the top competitors of Hugel?

Hugel's top competitors include Revance Therapeutics, Lineage Cell Therapeutics and Evolus. Among them, Shaperon secured the most recent funding round in April, 2026.

Hugel - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics in the field of aesthetics. Botulinum toxin products developed from the bacterial strain Clostridium Botulinum CBFC26, which is utilized in pediatric cerebral palsy patients, are available from the company. Other items the company offers include Chaeum Premium, a biomaterial for tissue restoration.

Key Metrics

Founded Year

2001

Location

Chuncheon-si, South Korea

Stage

Acquired

Last Known Valuation

$***** as on Jun 06, 2017

Investors

Mubadala & 15 more

Ranked

7^th among 173 active competitors

Employee Count

6 as on May 31, 2026

Investment & Acquisitions

J World

Similar Companies

Revance Therapeutics & 229 more

Exit Details

Acquired by CBC Group (May 24, 2022)

View Hugel's full profile

Hugel is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Hugel Co., Ltd. CIN: 211-87-04515 , South Korea, Active	Nov 21, 2001	$219M (As on Dec 31, 2022)	-	-

Hugel got acquired by CBC Group, GS Holdings, Mubadala and IMM Investment on May 24, 2022.

Click here to take a look at Hugel's acquisition in detail

Hugel is a funded company. Hugel has 16 institutional investors.

View details of Hugel's funding rounds and investors

Hugel's employee count trend

Hugel has 6 employees as of May 26. Here is Hugel's employee count trend over the years:

Uncover Hugel's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Hugel include Revance Therapeutics, Lineage Cell Therapeutics and Evolus. Here is the list of Top 10 competitors of Hugel, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Revance Therapeutics 2002, Newark (United States), Acquired	Developer of neurotoxin aesthetic and therapeutic products for skin treatments	$155M	EW Healthcare Partners, Delphi Ventures & 16 others	70/100
2nd	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$45.8M	State of California, Juvenescence & 4 others	65/100
3rd	Evolus 2012, Irvine (United States), Public	Developer of aesthetic treatments and procedures	$500K	Daewoong Pharmaceutical, De novo ventures	62/100
4th	Biofrontera 1997, Leverkusen (Germany), Public	Developer of therapies for actinic keratosis using photodynamic therapy	-	Rosalind Advisors, Deutsche Balaton & 1 others	62/100
5th	Dermavant 2016, Phoenix (United States), Acquired	Developer of small molecule based therapeutics for the treatment of inflammatory skin diseases	$160M	Marathon Asset Management, NovaQuest Capital Management ... Read more	61/100
6th	Sol-Gel Technologies 1998, United States, Public	Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.	$26M	Westwicke, Arkin Holdings & 6 others	59/100
7th	Hugel 2001, Chuncheon-si (South Korea), Acquired	Developer of therapeutics in the field of aesthetics	-	Mubadala, SKS Private Equity & 14 others	59/100
8th	Collplant 2004, Ness Ziona (Israel), Public	Developer of recombinant human collagen for regenerative medicine and aesthetics	$16.3M	Invesco, Pontifax & 4 others	59/100
9th	Shaperon 2008, Seoul (South Korea), Public	Developer of therapies for multiple diseases	-	Samsung Securities, Mirae Asset & 6 others	56/100
10th	AiVita Biomedical 2016, Irvine (United States), Series B	Developer of dendritic cell immunotherapy for cancer and markets stem cells based facial serum for skin care	$46M	California Technology Ventures, Ci:z Investment ... & 5 others	55/100